Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

Paper. Simonsson O, Bradley M, Black JC et al.. JAMA Network Open, 1 Sep 2026.

Tags: Psilocybin, MDMA, LSD, 5-MeO-DMT, Ibogaine.

Weekly Science Digest, 26 Sep 2026 to 2 Oct 2026, finding 2: Safety evidence came from surveys and case notes

This week's safety data are observational, and one case report documents psilocybin making things worse.

JAMA Network Open published a nationally representative US cross-sectional survey of health outcomes attributed to recent psilocybin, LSD, MDMA, ibogaine and 5-MeO-DMT use. A separate case report describes worsening depression and anxiety after psilocybin in cyclothymia, and an Oregon risk-reduction consult service (n=29) found most patients low-risk, with 17% reporting a prior challenging experience.

Read the original

—
Node—
Statuslive
Throughput—